Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma A Phase 3 Randomized Clinical Trial

Qin, SK; Kudo, M; Meyer, T; Bai, YX; Guo, YB; Meng, ZQ; Satoh, T; Marino, D; Assenat, E; Li, SZ; Chen, YX; Boisserie, F; Abdrashitov, R; Finn, RS; Vogel, A; Zhu, AX

Qin, SK (通讯作者)，China Pharmaceut Univ, Nanjing Tianyinshang Hosp, 3789 Jieyin Rd,Jiangning Dist, Nanjing 211102, Jiangsu, Peoples R China.

JAMA ONCOLOGY, 2023; 9 (12): 1651

Abstract

ImportanceHepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programm......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索